Adults aged 80 and older with chronic kidney disease had lower mortality over two years with SGLT2 inhibitor use than matched nonusers. Individualized assessment remains necessary.
ASN: Elderly with chronic kidney disease benefit from SGLT2 inhibitors
Sodium-glucose cotransporter 2 (SGLT2) inhibitors show significant benefits for adults aged 80 years and older with chronic kidney disease (CKD), according to a study presented at Kidney Week, the annual meeting of the American Society of Nephrology, held from Oct.
medicalxpress.com
November 3, 2026 at 3:27 PM
Adults aged 80 and older with chronic kidney disease had lower mortality over two years with SGLT2 inhibitor use than matched nonusers. Individualized assessment remains necessary.
【SGLT2-iは貧血に影響？RCTメタ解析/Heart】Oct.30
RCT 7報とRCT併合解析2報併合——
・SGLT2-iでプラセボに比べ、ヘモグロビンは0.66 g/dLの有意高
値。
・ヘマトクリットも2.0 %の有意高値。
・一方、フェリチンは15 %の有意低値。
全文🔗 qr.paps.jp/nZxIw
RCT 7報とRCT併合解析2報併合——
・SGLT2-iでプラセボに比べ、ヘモグロビンは0.66 g/dLの有意高
値。
・ヘマトクリットも2.0 %の有意高値。
・一方、フェリチンは15 %の有意低値。
全文🔗 qr.paps.jp/nZxIw
November 2, 2026 at 12:04 AM
【SGLT2-iは貧血に影響？RCTメタ解析/Heart】Oct.30
RCT 7報とRCT併合解析2報併合——
・SGLT2-iでプラセボに比べ、ヘモグロビンは0.66 g/dLの有意高
値。
・ヘマトクリットも2.0 %の有意高値。
・一方、フェリチンは15 %の有意低値。
全文🔗 qr.paps.jp/nZxIw
RCT 7報とRCT併合解析2報併合——
・SGLT2-iでプラセボに比べ、ヘモグロビンは0.66 g/dLの有意高
値。
・ヘマトクリットも2.0 %の有意高値。
・一方、フェリチンは15 %の有意低値。
全文🔗 qr.paps.jp/nZxIw
ASN: los inhibidores del SGLT2 benefician a los mayores con enfermedad renal crónica
ASN: los inhibidores del SGLT2 benefician a los mayores con enfermedad renal crónica
Healthday Spanish
dlvr.it
November 2, 2026 at 5:41 PM
ASN: los inhibidores del SGLT2 benefician a los mayores con enfermedad renal crónica
Крупный метаанализ показал, что прием глифлозинов повышает концентрацию гемоглобина и уровень гематокрита при диабете, метаболических нарушениях и сердечно-сосудистых заболеваниях
https://nplus1.ru/news/2026/10/28/sglt2-inhibitors-hemoglobin
#главноезанеделю
https://nplus1.ru/news/2026/10/28/sglt2-inhibitors-hemoglobin
#главноезанеделю
November 1, 2026 at 2:15 PM
Крупный метаанализ показал, что прием глифлозинов повышает концентрацию гемоглобина и уровень гематокрита при диабете, метаболических нарушениях и сердечно-сосудистых заболеваниях
https://nplus1.ru/news/2026/10/28/sglt2-inhibitors-hemoglobin
#главноезанеделю
https://nplus1.ru/news/2026/10/28/sglt2-inhibitors-hemoglobin
#главноезанеделю
【2型DM心腎転帰比較 SGLT2-i vs. GLP-1RA：TriNetXデータベース/DOM】Nov.02
SGLT2-iかGLP-1RAを開始した2型DM中、PSマッチ可能だった25万例弱×2比較——
・SGLT2-iでGLP-1RAに比べ、「腎不全・死亡」HRは0.87の有意低
値。
・「死亡」のみでも0.90 [有意]。
・CV死亡は0.98 [95%CI 0.97-1.00]。
抄録🔗 qr.paps.jp/3vUEm
SGLT2-iかGLP-1RAを開始した2型DM中、PSマッチ可能だった25万例弱×2比較——
・SGLT2-iでGLP-1RAに比べ、「腎不全・死亡」HRは0.87の有意低
値。
・「死亡」のみでも0.90 [有意]。
・CV死亡は0.98 [95%CI 0.97-1.00]。
抄録🔗 qr.paps.jp/3vUEm
【備忘】Nov.12
EJPC誌にTriNetXデータベースを用いた研究のデザインにまつわる問題点を指摘するレター [詳細不詳]。「検定力の観点から使用が増えているが、方法論を詳細に検討しないとバイアスのかかった結果になる可能性がある」との記載。
x.gd/Q9NaA
EJPC誌にTriNetXデータベースを用いた研究のデザインにまつわる問題点を指摘するレター [詳細不詳]。「検定力の観点から使用が増えているが、方法論を詳細に検討しないとバイアスのかかった結果になる可能性がある」との記載。
x.gd/Q9NaA
November 3, 2026 at 8:39 PM
【2型DM心腎転帰比較 SGLT2-i vs. GLP-1RA：TriNetXデータベース/DOM】Nov.02
SGLT2-iかGLP-1RAを開始した2型DM中、PSマッチ可能だった25万例弱×2比較——
・SGLT2-iでGLP-1RAに比べ、「腎不全・死亡」HRは0.87の有意低
値。
・「死亡」のみでも0.90 [有意]。
・CV死亡は0.98 [95%CI 0.97-1.00]。
抄録🔗 qr.paps.jp/3vUEm
SGLT2-iかGLP-1RAを開始した2型DM中、PSマッチ可能だった25万例弱×2比較——
・SGLT2-iでGLP-1RAに比べ、「腎不全・死亡」HRは0.87の有意低
値。
・「死亡」のみでも0.90 [有意]。
・CV死亡は0.98 [95%CI 0.97-1.00]。
抄録🔗 qr.paps.jp/3vUEm
#25 Empagliflozin (JARDIANCE)
SGLT2 inhibitor with cardiovascular and renal outcome benefits.
Mascot: Empty Jar dance
ballicules.com/drug/empagli...
#PharmSky #empagliflozin #pharmacystudent #top200drugs
SGLT2 inhibitor with cardiovascular and renal outcome benefits.
Mascot: Empty Jar dance
ballicules.com/drug/empagli...
#PharmSky #empagliflozin #pharmacystudent #top200drugs
November 4, 2026 at 3:11 PM
#25 Empagliflozin (JARDIANCE)
SGLT2 inhibitor with cardiovascular and renal outcome benefits.
Mascot: Empty Jar dance
ballicules.com/drug/empagli...
#PharmSky #empagliflozin #pharmacystudent #top200drugs
SGLT2 inhibitor with cardiovascular and renal outcome benefits.
Mascot: Empty Jar dance
ballicules.com/drug/empagli...
#PharmSky #empagliflozin #pharmacystudent #top200drugs
SGLT2阻害薬は人類の進化を先取りするという点でエンハンスメント的なものと解釈できるので、これを拡大解釈して人体を後付けオプションで強化することができないかと思っている
November 3, 2026 at 12:31 AM
SGLT2阻害薬は人類の進化を先取りするという点でエンハンスメント的なものと解釈できるので、これを拡大解釈して人体を後付けオプションで強化することができないかと思っている
"The increase ... is likely not just due to hemoconcentration." -- Michele Eisenga, MD, PhD, of University Medical Center Groningen, on data linking SGLT2 inhibitors with increases in hemoglobin and hematocrit levels. #KidneyWk @asnkidney.bsky.social www.medpagetoday.com/meetingcover...
SGLT2 Inhibitors Tied to Uptick in Hemoglobin and Hematocrit
'Modest rise' in hemoglobin concentration could still help in chronic anemia management
www.medpagetoday.com
November 2, 2026 at 2:55 PM
"The increase ... is likely not just due to hemoconcentration." -- Michele Eisenga, MD, PhD, of University Medical Center Groningen, on data linking SGLT2 inhibitors with increases in hemoglobin and hematocrit levels. #KidneyWk @asnkidney.bsky.social www.medpagetoday.com/meetingcover...
NRF2 plays an important role in the progression of diabetic kidney disease in Akita mice; renal NRF2 inhibition may therefore be a promising novel therapeutic avenue for DKD #Nrf2KO, #DKD, #CKD, #SGLT2 link.springer.com/article/10.1... 🔓
October 28, 2026 at 12:03 PM
NRF2 plays an important role in the progression of diabetic kidney disease in Akita mice; renal NRF2 inhibition may therefore be a promising novel therapeutic avenue for DKD #Nrf2KO, #DKD, #CKD, #SGLT2 link.springer.com/article/10.1... 🔓
【2型DM例がSGLT2-i服用でMASLDはどう変化？/JDI】Nov.02
イラン、MASLD合併2型DM 30例観察——
・SGLT2-i服用12週間後、AST、ALTとも有意に低下。
・脂肪肝 [CAPスコア]、肝硬度 [LSM]も同様に有意低下。
全文🔗 qr.paps.jp/Mes9f
イラン、MASLD合併2型DM 30例観察——
・SGLT2-i服用12週間後、AST、ALTとも有意に低下。
・脂肪肝 [CAPスコア]、肝硬度 [LSM]も同様に有意低下。
全文🔗 qr.paps.jp/Mes9f
Changes in liver steatosis and liver stiffness following Empagliflozin treatment in patients with <fc>MASLD</fc> and type 2 diabetes: A single‐arm pre–post study
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in subjects with type 2 diabetes mellitus (T2DM), being linked to a higher risk for the development of liver-rel...
qr.paps.jp
November 3, 2026 at 8:31 PM
【2型DM例がSGLT2-i服用でMASLDはどう変化？/JDI】Nov.02
イラン、MASLD合併2型DM 30例観察——
・SGLT2-i服用12週間後、AST、ALTとも有意に低下。
・脂肪肝 [CAPスコア]、肝硬度 [LSM]も同様に有意低下。
全文🔗 qr.paps.jp/Mes9f
イラン、MASLD合併2型DM 30例観察——
・SGLT2-i服用12週間後、AST、ALTとも有意に低下。
・脂肪肝 [CAPスコア]、肝硬度 [LSM]も同様に有意低下。
全文🔗 qr.paps.jp/Mes9f
【CKD入院例へのSGLT2-i開始後eGFR低下で死亡リスク増？/CKJ】Oct.29
中国公的DB、CKD入院後にSGLT2-i開始の1,258例 [平均64歳] 解析——
・23%で20%以上のeGFR「低下」。
・「非低下」例に比べIPTW後比較で45日間「死亡」HRは8.08の有
意高
値。
・一方、「45日後〜1年後」の比較では有意差なし。
抄録🔗 x.gd/UlP3M PDF全文Free
中国公的DB、CKD入院後にSGLT2-i開始の1,258例 [平均64歳] 解析——
・23%で20%以上のeGFR「低下」。
・「非低下」例に比べIPTW後比較で45日間「死亡」HRは8.08の有
意高
値。
・一方、「45日後〜1年後」の比較では有意差なし。
抄録🔗 x.gd/UlP3M PDF全文Free
Substantial Declines in eGFR After Initiation of SGLT2-Inhibitors Associate with Increased Short-term Mortality in Hospitalized Patients With CKD
AbstractBackground. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are recommended as first-line therapy for patients with chronic kidney disease (CKD)
x.gd
October 29, 2026 at 10:56 PM
【CKD入院例へのSGLT2-i開始後eGFR低下で死亡リスク増？/CKJ】Oct.29
中国公的DB、CKD入院後にSGLT2-i開始の1,258例 [平均64歳] 解析——
・23%で20%以上のeGFR「低下」。
・「非低下」例に比べIPTW後比較で45日間「死亡」HRは8.08の有
意高
値。
・一方、「45日後〜1年後」の比較では有意差なし。
抄録🔗 x.gd/UlP3M PDF全文Free
中国公的DB、CKD入院後にSGLT2-i開始の1,258例 [平均64歳] 解析——
・23%で20%以上のeGFR「低下」。
・「非低下」例に比べIPTW後比較で45日間「死亡」HRは8.08の有
意高
値。
・一方、「45日後〜1年後」の比較では有意差なし。
抄録🔗 x.gd/UlP3M PDF全文Free
Treatment with SGLT2 inhibitors was linked with modest but statistically significant increases in hemoglobin & hematocrit levels across a broad spectrum of patient populations, according to a systematic review & meta-analysis. #KidneyWk https://www.medpagetoday.com/meetingcoverage/asn/123568
SGLT2 Inhibitors Tied to Uptick in Hemoglobin and Hematocrit
'Modest rise' in hemoglobin concentration could still help in chronic anemia management
www.medpagetoday.com
October 26, 2026 at 7:28 PM
Treatment with SGLT2 inhibitors was linked with modest but statistically significant increases in hemoglobin & hematocrit levels across a broad spectrum of patient populations, according to a systematic review & meta-analysis. #KidneyWk https://www.medpagetoday.com/meetingcoverage/asn/123568
Urinary dipstick findings and UTI risk with SGLT2 inhibitors: a post-hoc analysis of the CANVAS and CREDENCE trials
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
Urinary dipstick findings and UTI risk with SGLT2 inhibitors: a post-hoc analysis of the CANVAS and CREDENCE trials
ABSTRACTBackground. Despite established cardiorenal benefits, concerns about urinary tract infection (UTI) risk may limit sodium-glucose cotransporter 2 in
academic.oup.com
October 28, 2026 at 2:08 PM
Urinary dipstick findings and UTI risk with SGLT2 inhibitors: a post-hoc analysis of the CANVAS and CREDENCE trials
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
Крупный метаанализ показал, что прием глифлозинов повышает концентрацию гемоглобина и уровень гематокрита при диабете, метаболических нарушениях и сердечно-сосудистых заболеваниях
https://nplus1.ru/news/2026/10/28/sglt2-inhibitors-hemoglobin
https://nplus1.ru/news/2026/10/28/sglt2-inhibitors-hemoglobin
October 28, 2026 at 2:32 PM
Крупный метаанализ показал, что прием глифлозинов повышает концентрацию гемоглобина и уровень гематокрита при диабете, метаболических нарушениях и сердечно-сосудистых заболеваниях
https://nplus1.ru/news/2026/10/28/sglt2-inhibitors-hemoglobin
https://nplus1.ru/news/2026/10/28/sglt2-inhibitors-hemoglobin
【SGLT2-iでHb/Htとも有意に上昇：RCTメタ解析/JAMA】Oct.24
CVD/DM/HF/CKD対象RCT 85報併合 [70,543例]——
・SGLT2阻害薬24週間でHbは「0.55」g/Lの有意増加。対照
群では「−0.08」。
・ヘマトクリットも2.2 vs. −0.1 %。
全文🔗 qr.paps.jp/Huoiz
CVD/DM/HF/CKD対象RCT 85報併合 [70,543例]——
・SGLT2阻害薬24週間でHbは「0.55」g/Lの有意増加。対照
群では「−0.08」。
・ヘマトクリットも2.2 vs. −0.1 %。
全文🔗 qr.paps.jp/Huoiz
October 26, 2026 at 1:17 AM
【SGLT2-iでHb/Htとも有意に上昇：RCTメタ解析/JAMA】Oct.24
CVD/DM/HF/CKD対象RCT 85報併合 [70,543例]——
・SGLT2阻害薬24週間でHbは「0.55」g/Lの有意増加。対照
群では「−0.08」。
・ヘマトクリットも2.2 vs. −0.1 %。
全文🔗 qr.paps.jp/Huoiz
CVD/DM/HF/CKD対象RCT 85報併合 [70,543例]——
・SGLT2阻害薬24週間でHbは「0.55」g/Lの有意増加。対照
群では「−0.08」。
・ヘマトクリットも2.2 vs. −0.1 %。
全文🔗 qr.paps.jp/Huoiz
A potential new role for SGLT2 inhibitors in ANOCA? Empagliflozin was associated with improved angina for these patients in a small pilot study and might even help reverse endothelial dysfunction, though experts caution that the findings are preliminary. https://bit.ly/4ySBapY
SGLT2 Inhibition Promising in ANOCA Patients With Microvascular Dysfunction
Angina symptoms improved in the 11-patient study, with signs that endothelial dysfunction may reverse with treatment.
bit.ly
October 25, 2026 at 9:00 PM
A potential new role for SGLT2 inhibitors in ANOCA? Empagliflozin was associated with improved angina for these patients in a small pilot study and might even help reverse endothelial dysfunction, though experts caution that the findings are preliminary. https://bit.ly/4ySBapY
📊 Meta-analysis: In patients with cardiovascular disease, #HeartFailure, #ChronicKidneyDisease, or #diabetes, #SGLT2 inhibitors were associated with small increases in hemoglobin and hematocrit vs control.
#KidneyWk @asnkidney.bsky.social
ja.ma/4eLJwYo
#KidneyWk @asnkidney.bsky.social
ja.ma/4eLJwYo
October 24, 2026 at 8:00 PM
📊 Meta-analysis: In patients with cardiovascular disease, #HeartFailure, #ChronicKidneyDisease, or #diabetes, #SGLT2 inhibitors were associated with small increases in hemoglobin and hematocrit vs control.
#KidneyWk @asnkidney.bsky.social
ja.ma/4eLJwYo
#KidneyWk @asnkidney.bsky.social
ja.ma/4eLJwYo
SGLT2 inhibitors (diabetes/HF drugs) raise hemoglobin +0.60 g/dL vs control (95% CI 0.55-0.66, P<.001) across 85 RCTs, n=70,543 - driven by a real EPO rise, not just plasma dilution.
An underrated extra benefit. jamanetwork.com/journals/jam...
An underrated extra benefit. jamanetwork.com/journals/jam...
October 25, 2026 at 12:32 PM
SGLT2 inhibitors (diabetes/HF drugs) raise hemoglobin +0.60 g/dL vs control (95% CI 0.55-0.66, P<.001) across 85 RCTs, n=70,543 - driven by a real EPO rise, not just plasma dilution.
An underrated extra benefit. jamanetwork.com/journals/jam...
An underrated extra benefit. jamanetwork.com/journals/jam...
Systematic review of CV outcomes w/ SGLT2 inhibitors- 5 studies, 11,190 IMID pts (SSc 25%, SLE 71%) SGLT2i use assoc w/ signif lower all-cause mortality and heart failure risk (no clear MI benefit). SGLT2i have establ use in NIDDM, CHF & CKD Pts. buff.ly/uBaeMHA
October 26, 2026 at 7:00 PM
Systematic review of CV outcomes w/ SGLT2 inhibitors- 5 studies, 11,190 IMID pts (SSc 25%, SLE 71%) SGLT2i use assoc w/ signif lower all-cause mortality and heart failure risk (no clear MI benefit). SGLT2i have establ use in NIDDM, CHF & CKD Pts. buff.ly/uBaeMHA
💬 Editorial: #SGLT2 inhibitors consistently increase hemoglobin, an effect that may add to their cardiovascular and kidney benefits and may support anemia management in selected patients.
ja.ma/4z6S4S3
#KidneyWk @asnkidney.bsky.social
ja.ma/4z6S4S3
#KidneyWk @asnkidney.bsky.social
October 24, 2026 at 8:00 PM
💬 Editorial: #SGLT2 inhibitors consistently increase hemoglobin, an effect that may add to their cardiovascular and kidney benefits and may support anemia management in selected patients.
ja.ma/4z6S4S3
#KidneyWk @asnkidney.bsky.social
ja.ma/4z6S4S3
#KidneyWk @asnkidney.bsky.social